COPENHAGEN — The antibiotics doctors reach for first are failing against two common hospital bacteria in about half of the reporting countries in the WHO European Region, the World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC) said on Wednesday, warning that patients are running out of treatment options.
Source: UN News, Nov 18, 2026
In a joint analysis published in Copenhagen on 18 November, WHO/Europe and the ECDC said that in 21 of the 43 countries that reported 2025 data, half or more of samples of Klebsiella pneumoniae — a common hospital bacterium that can cause serious bloodstream infections — were resistant to third-generation cephalosporins, a group of widely used antibiotics.
Source: WHO Regional Office for Europe, Nov 18, 2026
First-choice antibiotics are failing
"In many countries in our Region, the antibiotics doctors usually reach for first are failing against serious hospital infections," said Dr Marc-Alain Widdowson, Programme Manager in the Health Security Division at WHO/Europe. "So doctors turn to carbapenems, stronger drugs normally kept for the most serious cases. When those stop working too, what's left is mostly a small group of last-resort drugs that are often expensive and not available in every country."
That fallback is also narrowing. In 10 of the 43 reporting countries, half or more of Klebsiella pneumoniae samples resisted even carbapenems. For Acinetobacter, another bacterium that spreads in hospitals, half or more of samples resisted carbapenems in 21 of 38 reporting countries. "Each time one of these lines of defence falls, patients move closer to having no good options," Dr Widdowson said. "People whose first antibiotic doesn't work against their infection are more likely to die in hospital."
Two of three EU targets now further away
The European Union set three targets in 2023 to cut bloodstream infections from resistant bacteria by 2030, measured from 2019. Two are now further out of reach than when they were set: infections with carbapenem-resistant Klebsiella pneumoniae rose by an estimated 72% between 2019 and 2025 instead of falling 5%, and infections with E. coli resistant to third-generation cephalosporins rose by an estimated 16.4% instead of falling 10%. The third target — a 15% cut in MRSA infections — has been met early, with an estimated 19% fall, although infection rates have risen again in the last two years. In one piece of good news, the estimated rate of bloodstream infections with resistant Acinetobacter has almost halved since its high levels in 2021, during the COVID-19 pandemic.
What is solid
- The figures come from 2025 laboratory data gathered by two surveillance networks — EARS-Net, covering all 30 EU/EEA countries, and CAESAR, covering 17 more countries in the WHO European Region
- Resistance was measured in bacteria taken from blood and cerebrospinal fluid samples of patients with serious infections
- MRSA bloodstream infections in the EU fell by an estimated 19% between 2019 and 2025, meeting the 15% reduction target early
What is only claimed
- National surveillance systems differ, so the report cautions that results are not directly comparable between countries and cover only the countries that reported each bacterium–antibiotic combination, not all 53 WHO European Member States
- "Resistant" is a laboratory finding — it means the antibiotic is unlikely to work against the tested bacterium; the report measures laboratory results, not patient treatment outcomes
Planning half-blind
Many countries still cannot see the full scale of the problem. Of the 51 countries with data, 16 — almost one in three — still collect resistance data without a standardized national approach and national coordination. In hospitals where few blood samples are taken, doctors often have to choose an antibiotic without knowing which will work, and health systems are, in WHO's words, "planning half-blind". Almost every country in the Region (94%) reports having a national action plan on antimicrobial resistance or revising one, but only 40% are carrying it out with funding in place and regular checks on progress.
This Europe report lands two days after WHO headquarters in Geneva warned that drug-resistant infections could kill 39 million people over the next 25 years and that most countries' AMR plans remain unfunded. The European data now shows what that warning looks like on hospital wards in one region. Read the earlier global WHO warning
What happens next: WHO/Europe is calling on countries to fund and carry out their national plans, strengthen infection control in hospitals, use carbapenems and last-resort drugs carefully, invest in laboratories and routine blood cultures, and make sure last-resort antibiotics are available where patients need them. With the London School of Economics and support from the Novo Nordisk Foundation, WHO/Europe is finalizing an Antimicrobial Resistance Accountability Index, piloted in six countries in 2026. For India and Punjab — where antibiotics are widely bought without prescription and hospital infection control varies sharply — the European numbers carry a direct warning: resistance built up in one region's hospitals does not stay in that region.
